论文部分内容阅读
目的观察巴曲酶联合维脑路通治疗急性脑梗塞的临床疗效。方法将96例急性脑梗塞患者随机分为治疗组(50例)和对照组(46例),两组均应用常规治疗及维脑路通作基础用药;治疗组加用巴曲酶治疗。两组进行对照观察。结果治疗组总有效率94%,明显高于对照组(P<0.05),治疗组治疗后神经功能缺损评分较治疗前显著下降,纤维蛋白原(Fg)较治疗前降低,纤溶酶(PL)较治疗前升高,无明显不良反应。结论巴曲酶联合维脑路通治疗急性脑梗塞疗效好,且安全。
Objective To observe the clinical efficacy of batroxobin and venlaton in the treatment of acute cerebral infarction. Methods A total of 96 patients with acute cerebral infarction were randomly divided into treatment group (n = 50) and control group (n = 46). Both groups were treated with conventional therapy and Viagra et al. The treatment group was treated with batroxobin. Two groups were observed. Results The total effective rate was 94% in the treatment group, which was significantly higher than that in the control group (P <0.05). The score of neurological deficit in the treatment group decreased significantly after treatment compared with that before treatment. The fibrinogen (Fg) ) Than before treatment, no obvious adverse reactions. Conclusion Batroxobin combined with Venoruton in the treatment of acute cerebral infarction is effective and safe.